Zealand Pharma — September 2022
-
Jeg er ret omfattende investeret i virksomheden, fordi jeg vurderer, den har et stort potentiale for udvikling og vækst. Det er ikke gambling, men medejerskab af en virksomhed. Bevares, jeg er meget spændt på udfaldet af SBS, men min investering står og
falder ikke med resultatet. -
Risikoappetit er jo en smagssag og smag kan ikke rigtig diskuteres, vil nogen påstå. Anyways husk at SBS kan fejle såvel meget andet og det er jo klassisk bio risk og så kommer der vel en emission i starten af 2023. Vil være overrasket hvis selskabet begynder, at trække på lånefaciliteter for, at finansiere sin RD uden, at have udsigt til stabile indtægter. Det er endnu mere high risk, at geare forretningen med lån, hvis indtægterne ikke er tilstede set fra et strategisk synspunkt.
-
Hej alle, Tak for at dele jeres synspunkter. Det er helt korrekt, at det er helt individuelt hvor risikovillig man er. Jeg er ikke langsigtet i Zealand, og det betyder at der er ret meget på spil for mig mht. fase3 SBS. Jeg tør ikke at tage risikoen, hvorfor jeg i dag har solgt ud og taget gevinst hjem. Held og lykke til alle jer andre.
-
“We are very pleased to present the compelling results from the Phase 3 study of dasiglucagon in newborns and infants up to 12 months of age at ESPE 2022. This study deepens our understanding of dasiglucagon’s potential as an innovative treatment for CHI patients,” said David Kendall, M.D., Chief Medical Officer of Zealand Pharma. "Zealand is committed to addressing the unmet needs of children living with CHI and we look forward to engaging with regulatory authorities and submitting a New Drug A
-
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting...
-
-
Zealand Pharma sagsøgt for misbrug af forretningshemmeligheder
Da et potentielt samarbejde kuldsejlede, tog Zealand Pharma fortrolig viden fra modparten med sig. Det mener et græsk biotekselskab, der har sagsøgt Zealand Pharma i Danmark og USA.
(medwatch.dk)
-
-
-
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European...
GlobeNewswire News Room (www.globenewswire.com)
*BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase
-
“We are delighted with the data presented at EASD from Boehringer Ingelheim’s Phase 2 trial of the dual glucagon/GLP-1 receptor agonist BI 456906 that showed effective lowering of HbA1c of up to -1.88% in people with type 2 diabetes at 16 weeks compared to -1.47% observed following open-label treatment with the GLP-1 receptor agonist semaglutide,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma.
-
Zealand Pharma har afgørende data klar om få uger. Zealand Pharma har afsluttet sit fase 3-forsøg med lægemiddelkandidaten glepaglutid og venter nu på de afgørende data, så de kan deles med offentligheden.
Det skriver Finans. https://medwatch.dk/Medicinal___Biotek/article14425346.ece?utm_campaign=MedWatch Morgen&utm_content=2022-09-22&utm_medium=email&utm_source=medwatch
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind